|
Jul 24
|
Theravance Biopharma, Inc. (NASDAQ:TBPH): When Will It Breakeven?
|
|
Jun 21
|
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
|
|
Mar 27
|
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
|
|
Jan 12
|
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
|
|
Jan 5
|
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
|
|
Dec 21
|
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
|
|
Dec 18
|
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
|
|
Dec 9
|
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable
|
|
Dec 7
|
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?
|
|
Oct 19
|
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
|
|
Aug 31
|
12 High Growth Value Stocks to Buy According to Seth Klarman
|
|
Aug 29
|
Theravance Biopharma to Participate in an Upcoming Investor Conference
|
|
Aug 28
|
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
|